Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

β-Amyloid accumulation in the human brain after one night of sleep deprivation.

Shokri-Kojori E, Wang GJ, Wiers CE, Demiral SB, Guo M, Kim SW, Lindgren E, Ramirez V, Zehra A, Freeman C, Miller G, Manza P, Srivastava T, De Santi S, Tomasi D, Benveniste H, Volkow ND.

Proc Natl Acad Sci U S A. 2018 Apr 24;115(17):4483-4488. doi: 10.1073/pnas.1721694115. Epub 2018 Apr 9.

2.

Validation of Noninvasive Tracer Kinetic Analysis of 18F-Florbetaben PET Using a Dual-Time-Window Acquisition Protocol.

Bullich S, Barthel H, Koglin N, Becker GA, De Santi S, Jovalekic A, Stephens AW, Sabri O.

J Nucl Med. 2018 Jul;59(7):1104-1110. doi: 10.2967/jnumed.117.200964. Epub 2017 Nov 24.

PMID:
29175981
3.

Patient and Caregiver Assessment of the Benefits From the Clinical Use of Amyloid PET Imaging.

Mustafa R, Brosch JR, Rabinovici GD, Dickerson BC, Carrillo MC, Glazier BS, Gao S, Tierney M, Fargo KN, Austrom MG, De Santi S, Clark DG, Apostolova LG.

Alzheimer Dis Assoc Disord. 2018 Jan-Mar;32(1):35-42. doi: 10.1097/WAD.0000000000000220.

PMID:
29140859
4.

18F-Florbetaben PET beta-amyloid binding expressed in Centiloids.

Rowe CC, Doré V, Jones G, Baxendale D, Mulligan RS, Bullich S, Stephens AW, De Santi S, Masters CL, Dinkelborg L, Villemagne VL.

Eur J Nucl Med Mol Imaging. 2017 Nov;44(12):2053-2059. doi: 10.1007/s00259-017-3749-6. Epub 2017 Jun 22.

5.

Optimized classification of 18F-Florbetaben PET scans as positive and negative using an SUVR quantitative approach and comparison to visual assessment.

Bullich S, Seibyl J, Catafau AM, Jovalekic A, Koglin N, Barthel H, Sabri O, De Santi S.

Neuroimage Clin. 2017 May 13;15:325-332. doi: 10.1016/j.nicl.2017.04.025. eCollection 2017.

6.

Optimal Reference Region to Measure Longitudinal Amyloid-β Change with 18F-Florbetaben PET.

Bullich S, Villemagne VL, Catafau AM, Jovalekic A, Koglin N, Rowe CC, De Santi S.

J Nucl Med. 2017 Aug;58(8):1300-1306. doi: 10.2967/jnumed.116.187351. Epub 2017 Feb 9.

7.

Advances in Aβ plaque detection and the value of knowing: overcoming challenges to improving patient outcomes in Alzheimer's disease.

Jovalekic A, Bullich S, Catafau A, de Santi S.

Neurodegener Dis Manag. 2016 Dec;6(6):491-497. Epub 2016 Nov 4. Review.

PMID:
27813444
8.

Perspective: The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partner Scientific Board (PPSB).

Liu E, Luthman J, Cedarbaum JM, Schmidt ME, Cole PE, Hendrix J, Carrillo MC, Jones-Davis D, Tarver E, Novak G, De Santi S, Soares HD, Potter WZ, Siemers E, Schwarz AJ.

Alzheimers Dement. 2015 Jul;11(7):840-9. doi: 10.1016/j.jalz.2015.04.001. Review.

PMID:
26194317
9.

The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data.

Schmidt ME, Chiao P, Klein G, Matthews D, Thurfjell L, Cole PE, Margolin R, Landau S, Foster NL, Mason NS, De Santi S, Suhy J, Koeppe RA, Jagust W; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2015 Sep;11(9):1050-68. doi: 10.1016/j.jalz.2014.09.004. Epub 2014 Nov 24. Review.

10.

Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans.

Bakken TE, Roddey JC, Djurovic S, Akshoomoff N, Amaral DG, Bloss CS, Casey BJ, Chang L, Ernst TM, Gruen JR, Jernigan TL, Kaufmann WE, Kenet T, Kennedy DN, Kuperman JM, Murray SS, Sowell ER, Rimol LM, Mattingsdal M, Melle I, Agartz I, Andreassen OA, Schork NJ, Dale AM; Alzheimer's Disease Neuroimaging Initiative; Pediatric Imaging, Neurocognition, and Genetics Study, Weiner M, Aisen P, Petersen R, Jack CR Jr, Jagust W, Trojanowki JQ, Toga AW, Beckett L, Green RC, Saykin AJ, Morris J, Liu E, Montine T, Gamst A, Thomas RG, Donohue M, Walter S, Gessert D, Sather T, Harvey D, Kornak J, Dale A, Bernstein M, Felmlee J, Fox N, Thompson P, Schuff N, Alexander G, DeCarli C, Bandy D, Koeppe RA, Foster N, Reiman EM, Chen K, Mathis C, Cairns NJ, Taylor-Reinwald L, Trojanowki JQ, Shaw L, Lee VM, Korecka M, Crawford K, Neu S, Foroud TM, Potkin S, Shen L, Kachaturian Z, Frank R, Snyder PJ, Molchan S, Kaye J, Quinn J, Lind B, Dolen S, Schneider LS, Pawluczyk S, Spann BM, Brewer J, Vanderswag H, Heidebrink JL, Lord JL, Johnson K, Doody RS, Villanueva-Meyer J, Chowdhury M, Stern Y, Honig LS, Bell KL, Morris JC, Ances B, Carroll M, Leon S, Mintun MA, Schneider S, Marson D, Griffith R, Clark D, Grossman H, Mitsis E, Romirowsky A, deToledo-Morrell L, Shah RC, Duara R, Varon D, Roberts P, Albert M, Onyike C, Kielb S, Rusinek H, de Leon MJ, Glodzik L, De Santi S, Doraiswamy PM, Petrella JR, Coleman RE, Arnold SE, Karlawish JH, Wolk D, Smith CD, Jicha G, Hardy P, Lopez OL, Oakley M, Simpson DM, Porsteinsson AP, Goldstein BS, Martin K, Makino KM, Ismail MS, Brand C, Mulnard RA, Thai G, Mc-Adams-Ortiz C, Womack K, Mathews D, Quiceno M, Diaz-Arrastia R, King R, Weiner M, Martin-Cook K, DeVous M, Levey AI, Lah JJ, Cellar JS, Burns JM, Anderson HS, Swerdlow RH, Apostolova L, Lu PH, Bartzokis G, Silverman DH, Graff-Radford NR, Parfitt F, Johnson H, Farlow MR, Hake AM, Matthews BR, Herring S, van Dyck CH, Carson RE, MacAvoy MG, Chertkow H, Bergman H, Hosein C, Black S, Stefanovic B, Caldwell C, Ging-Yuek, Hsiung R, Feldman H, Mudge B, Assaly M, Kertesz A, Rogers J, Trost D, Bernick C, Munic D, Kerwin D, Mesulam MM, Lipowski K, Wu CK, Johnson N, Sadowsky C, Martinez W, Villena T, Turner RS, Johnson K, Reynolds B, Sperling RA, Johnson KA, Marshall G, Frey M, Yesavage J, Taylor JL, Lane B, Rosen A, Tinklenberg J, Sabbagh M, Belden C, Jacobson S, Kowall N, Killiany R, Budson AE, Norbash A, Johnson PL, Obisesan TO, Wolday S, Bwayo SK, Lerner A, Hudson L, Ogrocki P, Fletcher E, Carmichael O, Olichney J, Kittur S, Borrie M, Lee TY, Bartha R, Johnson S, Asthana S, Carlsson CM, Potkin SG, Preda A, Nguyen D, Tariot P, Fleisher A, Reeder S, Bates V, Capote H, Rainka M, Scharre DW, Kataki M, Zimmerman EA, Celmins D, Brown AD, Pearlson GD, Blank K, Anderson K, Santulli RB, Schwartz ES, Sink KM, Williamson JD, Garg P, Watkins F, Ott BR, Querfurth H, Tremont G, Salloway S, Malloy P, Correia S, Rosen HJ, Miller BL, Mintzer J, Longmire CF, Spicer K, Finger E, Rachinsky I, Drost D, Jernigan T, McCabe C, Grant E, Ernst T, Kuperman J, Chung Y, Murray S, Bloss C, Darst B, Pritchett L, Saito A, Amaral D, DiNino M, Eyngorina B, Sowell E, Houston S, Soderberg L, Kaufmann W, van Zijl P, Rizzo-Busack H, Javid M, Mehta N, Ruberry E, Powers A, Rosen B, Gebhard N, Manigan H, Frazier J, Kennedy D, Yakutis L, Hill M, Gruen J, Bosson-Heenan J, Carlson H.

Proc Natl Acad Sci U S A. 2012 Mar 6;109(10):3985-90. doi: 10.1073/pnas.1105829109. Epub 2012 Feb 16.

11.

Surgery and brain atrophy in cognitively normal elderly subjects and subjects diagnosed with mild cognitive impairment.

Kline RP, Pirraglia E, Cheng H, De Santi S, Li Y, Haile M, de Leon MJ, Bekker A; Alzheimerʼs Disease Neuroimaging Initiative.

Anesthesiology. 2012 Mar;116(3):603-12. doi: 10.1097/ALN.0b013e318246ec0b.

12.

Rater Training for a Multi-Site, International Clinical Trial: What Mood Symptoms may be most Difficult to Rate?

Sajatovic M, Gaur R, Tatsuoka C, De Santi S, Lee N, Laredo J, Tripathi S.

Psychopharmacol Bull. 2011 Sep 15;44(3):5-14.

13.

Errors in ADAS-cog administration and scoring may undermine clinical trials results.

Schafer K, De Santi S, Schneider LS.

Curr Alzheimer Res. 2011 Jun;8(4):373-6.

PMID:
21557720
14.

Alzheimer's disease markers, hypertension, and gray matter damage in normal elderly.

Glodzik L, Mosconi L, Tsui W, de Santi S, Zinkowski R, Pirraglia E, Rich KE, McHugh P, Li Y, Williams S, Ali F, Zetterberg H, Blennow K, Mehta P, de Leon MJ.

Neurobiol Aging. 2012 Jul;33(7):1215-27. doi: 10.1016/j.neurobiolaging.2011.02.012. Epub 2011 May 6.

15.

Maternal age affects brain metabolism in adult children of mothers affected by Alzheimer's disease.

Mosconi L, Tsui W, Murray J, McHugh P, Li Y, Williams S, Pirraglia E, Glodzik L, De Santi S, Vallabhajosula S, de Leon MJ.

Neurobiol Aging. 2012 Mar;33(3):624.e1-9. doi: 10.1016/j.neurobiolaging.2011.03.003. Epub 2011 Apr 22.

16.

Structural brain changes in normal individuals with a maternal history of Alzheimer's.

Berti V, Mosconi L, Glodzik L, Li Y, Murray J, De Santi S, Pupi A, Tsui W, De Leon MJ.

Neurobiol Aging. 2011 Dec;32(12):2325.e17-26. doi: 10.1016/j.neurobiolaging.2011.01.001. Epub 2011 Feb 12.

17.

Framingham cardiovascular risk profile correlates with impaired hippocampal and cortical vasoreactivity to hypercapnia.

Glodzik L, Rusinek H, Brys M, Tsui WH, Switalski R, Mosconi L, Mistur R, Pirraglia E, de Santi S, Li Y, Goldowsky A, de Leon MJ.

J Cereb Blood Flow Metab. 2011 Feb;31(2):671-9. doi: 10.1038/jcbfm.2010.145. Epub 2010 Sep 15.

18.

Oxidative stress and amyloid-beta pathology in normal individuals with a maternal history of Alzheimer's.

Mosconi L, Glodzik L, Mistur R, McHugh P, Rich KE, Javier E, Williams S, Pirraglia E, De Santi S, Mehta PD, Zinkowski R, Blennow K, Pratico D, de Leon MJ.

Biol Psychiatry. 2010 Nov 15;68(10):913-21. doi: 10.1016/j.biopsych.2010.07.011.

19.

Does mild cognitive impairment increase the risk of developing postoperative cognitive dysfunction?

Bekker A, Lee C, de Santi S, Pirraglia E, Zaslavsky A, Farber S, Haile M, de Leon MJ.

Am J Surg. 2010 Jun;199(6):782-8. doi: 10.1016/j.amjsurg.2009.07.042.

20.

Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer's.

Mosconi L, Rinne JO, Tsui WH, Berti V, Li Y, Wang H, Murray J, Scheinin N, Någren K, Williams S, Glodzik L, De Santi S, Vallabhajosula S, de Leon MJ.

Proc Natl Acad Sci U S A. 2010 Mar 30;107(13):5949-54. doi: 10.1073/pnas.0914141107. Epub 2010 Mar 15.

21.

Early detection of Alzheimer's disease with PET imaging.

Berti V, Osorio RS, Mosconi L, Li Y, De Santi S, de Leon MJ.

Neurodegener Dis. 2010;7(1-3):131-5. doi: 10.1159/000289222. Epub 2010 Mar 3. Review.

22.

Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging.

Mosconi L, Berti V, Glodzik L, Pupi A, De Santi S, de Leon MJ.

J Alzheimers Dis. 2010;20(3):843-54. doi: 10.3233/JAD-2010-091504. Review.

23.

Phosphorylated tau 231, memory decline and medial temporal atrophy in normal elders.

Glodzik L, de Santi S, Tsui WH, Mosconi L, Zinkowski R, Pirraglia E, Wang HY, Li Y, Rich KE, Zetterberg H, Blennow K, Mehta P, de Leon MJ.

Neurobiol Aging. 2011 Dec;32(12):2131-41. doi: 10.1016/j.neurobiolaging.2009.12.026. Epub 2010 Feb 4.

24.

Evaluation of Early Dementia (Mild Cognitive Impairment).

Osorio RS, Berti V, Mosconi L, Li Y, Glodzik L, De Santi S, de Leon MJ.

PET Clin. 2010 Jan;5(1):15-31. doi: 10.1016/j.cpet.2009.12.003. Epub 2010 May 27. Review.

PMID:
27157481
25.

Effects of memantine on cerebrospinal fluid biomarkers of neurofibrillary pathology.

Glodzik L, De Santi S, Rich KE, Brys M, Pirraglia E, Mistur R, Switalski R, Mosconi L, Sadowski M, Zetterberg H, Blennow K, de Leon MJ.

J Alzheimers Dis. 2009;18(3):509-13. doi: 10.3233/JAD-2009-1183.

26.

Magnetic resonance imaging improves cerebrospinal fluid biomarkers in the early detection of Alzheimer's disease.

Brys M, Glodzik L, Mosconi L, Switalski R, De Santi S, Pirraglia E, Rich K, Kim BC, Mehta P, Zinkowski R, Pratico D, Wallin A, Zetterberg H, Tsui WH, Rusinek H, Blennow K, de Leon MJ.

J Alzheimers Dis. 2009;16(2):351-62. doi: 10.3233/JAD-2009-0968.

27.

FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease.

Mosconi L, Mistur R, Switalski R, Tsui WH, Glodzik L, Li Y, Pirraglia E, De Santi S, Reisberg B, Wisniewski T, de Leon MJ.

Eur J Nucl Med Mol Imaging. 2009 May;36(5):811-22. doi: 10.1007/s00259-008-1039-z. Epub 2009 Jan 14.

28.

Declining brain glucose metabolism in normal individuals with a maternal history of Alzheimer disease.

Mosconi L, Mistur R, Switalski R, Brys M, Glodzik L, Rich K, Pirraglia E, Tsui W, De Santi S, de Leon MJ.

Neurology. 2009 Feb 10;72(6):513-20. doi: 10.1212/01.wnl.0000333247.51383.43. Epub 2008 Nov 12.

29.

Robust and conventional neuropsychological norms: diagnosis and prediction of age-related cognitive decline.

De Santi S, Pirraglia E, Barr W, Babb J, Williams S, Rogers K, Glodzik L, Brys M, Mosconi L, Reisberg B, Ferris S, de Leon MJ.

Neuropsychology. 2008 Jul;22(4):469-84. doi: 10.1037/0894-4105.22.4.469.

30.

An entorhinal cortex sulcal pattern is associated with Alzheimer's disease.

Zhan J, Brys M, Glodzik L, Tsui W, Javier E, Wegiel J, Kuchna I, Pirraglia E, Li Y, Mosconi L, Saint Louis LA, Switalski R, De Santi S, Kim BC, Wisniewski T, Reisberg B, Bobinski M, de Leon MJ.

Hum Brain Mapp. 2009 Mar;30(3):874-82. doi: 10.1002/hbm.20549.

31.

Memantine decreases hippocampal glutamate levels: a magnetic resonance spectroscopy study.

Glodzik L, King KG, Gonen O, Liu S, De Santi S, de Leon MJ.

Prog Neuropsychopharmacol Biol Psychiatry. 2008 May 15;32(4):1005-12. doi: 10.1016/j.pnpbp.2008.01.016. Epub 2008 Feb 7.

32.

Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism.

Mosconi L, Brys M, Switalski R, Mistur R, Glodzik L, Pirraglia E, Tsui W, De Santi S, de Leon MJ.

Proc Natl Acad Sci U S A. 2007 Nov 27;104(48):19067-72. Epub 2007 Nov 14.

33.

Longitudinal CSF isoprostane and MRI atrophy in the progression to AD.

de Leon MJ, Mosconi L, Li J, De Santi S, Yao Y, Tsui WH, Pirraglia E, Rich K, Javier E, Brys M, Glodzik L, Switalski R, Saint Louis LA, Pratico D.

J Neurol. 2007 Dec;254(12):1666-75. Epub 2007 Nov 14.

PMID:
17994313
34.

The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease.

Glodzik-Sobanska L, Pirraglia E, Brys M, de Santi S, Mosconi L, Rich KE, Switalski R, Saint Louis L, Sadowski MJ, Martiniuk F, Mehta P, Pratico D, Zinkowski RP, Blennow K, de Leon MJ.

Neurobiol Aging. 2009 May;30(5):672-81. Epub 2007 Oct 24.

35.

Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment.

Brys M, Pirraglia E, Rich K, Rolstad S, Mosconi L, Switalski R, Glodzik-Sobanska L, De Santi S, Zinkowski R, Mehta P, Pratico D, Saint Louis LA, Wallin A, Blennow K, de Leon MJ.

Neurobiol Aging. 2009 May;30(5):682-90. Epub 2007 Sep 24.

36.

Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints.

Mosconi L, De Santi S, Brys M, Tsui WH, Pirraglia E, Glodzik-Sobanska L, Rich KE, Switalski R, Mehta PD, Pratico D, Zinkowski R, Blennow K, de Leon MJ.

Biol Psychiatry. 2008 Mar 15;63(6):609-18. Epub 2007 Aug 27.

37.

Subjective memory complaints: presence, severity and future outcome in normal older subjects.

Glodzik-Sobanska L, Reisberg B, De Santi S, Babb JS, Pirraglia E, Rich KE, Brys M, de Leon MJ.

Dement Geriatr Cogn Disord. 2007;24(3):177-84. Epub 2007 Jul 17.

PMID:
17641528
38.

(18)F-FDG PET database of longitudinally confirmed healthy elderly individuals improves detection of mild cognitive impairment and Alzheimer's disease.

Mosconi L, Tsui WH, Pupi A, De Santi S, Drzezga A, Minoshima S, de Leon MJ.

J Nucl Med. 2007 Jul;48(7):1129-34. Epub 2007 Jun 15.

39.

Quantitation, regional vulnerability, and kinetic modeling of brain glucose metabolism in mild Alzheimer's disease.

Mosconi L, Tsui WH, Rusinek H, De Santi S, Li Y, Wang GJ, Pupi A, Fowler J, de Leon MJ.

Eur J Nucl Med Mol Imaging. 2007 Sep;34(9):1467-79. Epub 2007 Apr 4.

PMID:
17406865
40.

Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease.

Devanand DP, Pradhaban G, Liu X, Khandji A, De Santi S, Segal S, Rusinek H, Pelton GH, Honig LS, Mayeux R, Stern Y, Tabert MH, de Leon MJ.

Neurology. 2007 Mar 13;68(11):828-36.

PMID:
17353470
41.

Hippocampal hypometabolism predicts cognitive decline from normal aging.

Mosconi L, De Santi S, Li J, Tsui WH, Li Y, Boppana M, Laska E, Rusinek H, de Leon MJ.

Neurobiol Aging. 2008 May;29(5):676-92. Epub 2007 Jan 11.

42.

Early detection of Alzheimer's disease using neuroimaging.

Mosconi L, Brys M, Glodzik-Sobanska L, De Santi S, Rusinek H, de Leon MJ.

Exp Gerontol. 2007 Jan-Feb;42(1-2):129-38. Epub 2006 Jul 12. Review.

PMID:
16839732
43.

Hippocampal cerebrospinal fluid spaces on MR imaging: Relationship to aging and Alzheimer disease.

Li Y, Li J, Segal S, Wegiel J, De Santi S, Zhan J, de Leon MJ.

AJNR Am J Neuroradiol. 2006 Apr;27(4):912-8.

44.

The role of quantitative structural imaging in the early diagnosis of Alzheimer's disease.

Glodzik-Sobanska L, Rusinek H, Mosconi L, Li Y, Zhan J, de Santi S, Convit A, Rich K, Brys M, de Leon MJ.

Neuroimaging Clin N Am. 2005 Nov;15(4):803-26, x. Review.

PMID:
16443492
45.

Visual rating of medial temporal lobe metabolism in mild cognitive impairment and Alzheimer's disease using FDG-PET.

Mosconi L, De Santi S, Li Y, Li J, Zhan J, Tsui WH, Boppana M, Pupi A, de Leon MJ.

Eur J Nucl Med Mol Imaging. 2006 Feb;33(2):210-21. Epub 2005 Nov 26.

PMID:
16311757
46.

Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis.

Mosconi L, Tsui WH, De Santi S, Li J, Rusinek H, Convit A, Li Y, Boppana M, de Leon MJ.

Neurology. 2005 Jun 14;64(11):1860-7.

PMID:
15955934
47.

Absence of hippocampal volume differences in survivors of the Nazi Holocaust with and without posttraumatic stress disorder.

Golier JA, Yehuda R, De Santi S, Segal S, Dolan S, de Leon MJ.

Psychiatry Res. 2005 May 30;139(1):53-64.

PMID:
15939577
48.

Magnetic resonance and PET studies in the early diagnosis of Alzheimer's disease.

Mosconi L, De Santi S, Rusinek H, Convit A, de Leon MJ.

Expert Rev Neurother. 2004 Sep;4(5):831-49. Review.

PMID:
15853510
49.

Atrophy rate in medial temporal lobe during progression of Alzheimer disease.

Rusinek H, Endo Y, De Santi S, Frid D, Tsui WH, Segal S, Convit A, de Leon MJ.

Neurology. 2004 Dec 28;63(12):2354-9.

PMID:
15623699
50.

Imaging is superior to cognitive testing for early diagnosis of Alzheimer's disease.

Zamrini E, De Santi S, Tolar M.

Neurobiol Aging. 2004 May-Jun;25(5):685-91. Review.

PMID:
15172748

Supplemental Content

Loading ...
Support Center